Reproducibility of findings in modern PET neuroimaging: insight from the NRM2018 grand challenge

por Veronese, Mattia, Rizzo, Gaia, Belzunce, Martin, Schubert, Julia, Searle, Graham, Whittington, Alex, Mansur, Ayla, Dunn, Joel, Reader, Andrew, Gunn, Roger N
Publicado 2021

O11.3. SYNAPTIC MARKER PROTEIN SV2A IS REDUCED IN SCHIZOPHRENIA IN VIVO AND UNAFFECTED BY ANTIPSYCHOTICS IN RATS

por Chika Onwordi, Ellis, Halff, Els, Whitehurst, Thomas, Mansur, Ayla, Cotel, Marie-Caroline, Wells, Lisa, Creeney, Hannah, Bonsall, David, Rogdaki, Maria, Shatalina, Ekaterina, Reis Marques, Tiago, Rabiner, Eugenii, Gunn, Roger, Natesan, Sridhar, Vernon, Anthony, Howes, Oliver D
Publicado 2020

The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spec...

por Onwordi, Ellis Chika, Whitehurst, Thomas, Mansur, Ayla, Statton, Ben, Berry, Alaine, Quinlan, Marina, O’Regan, Declan P., Rogdaki, Maria, Marques, Tiago Reis, Rabiner, Eugenii A., Gunn, Roger N., Vernon, Anthony C., Natesan, Sridhar, Howes, Oliver D.
Publicado 2021

Endogenous dopamine release in the human brain as a pharmacodynamic biomarker: evaluation of the new GPR139 agonist TAK-041 with [(11)C]PHNO PET

por Rabiner, Eugenii A., Uz, Tolga, Mansur, Ayla, Brown, Terry, Chen, Grace, Wu, Jingtao, Atienza, Joy, Schwarz, Adam J., Yin, Wei, Lewis, Yvonne, Searle, Graham E., Dennison, Jeremy M. T. J., Passchier, Jan, Gunn, Roger N., Tauscher, Johannes
Publicado 2021

Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats

por Onwordi, Ellis Chika, Halff, Els F., Whitehurst, Thomas, Mansur, Ayla, Cotel, Marie-Caroline, Wells, Lisa, Creeney, Hannah, Bonsall, David, Rogdaki, Maria, Shatalina, Ekaterina, Reis Marques, Tiago, Rabiner, Eugenii A., Gunn, Roger N., Natesan, Sridhar, Vernon, Anthony C., Howes, Oliver D.
Publicado 2020